Citations

Clear

813 citation(s) found for "He, Helen".

Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Armstrong, Deborah K. , Alvarez, Ronald D. , Barroilhet, Lisa , Chen, Lee-may, Cristea, Mihaela , Eisenhauer, Eric , Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Karam, Amer , Konecny, Gottfried E. , Mahdi, Haider , McHale, Michael , Miller, David S. , O’Malley, David M. , Percac‐Lima, Sanja , Ratner, Elena , Remmenga, Steven W., Vargas, Roberto , Werner, Theresa L. , Zsíros, Emese , Burns, Jennifer L. , Engh, Anita M. , Miller, David S , O'Malley, David M , Bakkum‐Gamez, Jamie N. , Behbakht, Kian , Berchuck, Andrew , DeRosa, Maria, Gershenson, David M. , Grisham, Rachel Nicole , Leath, Charles A , Liu, Joyce F. , Martin, Lainie P. , Matei, Daniela , McLean, Karen

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 8, 2021 | Volume: 19 | Issue: 2 | Pages: 191-226

10.6004/jnccn.2021.0007 | PMID 33545690 Get It

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States and is the country’s fifth most common cause of cancer mortality in women. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. These NCCN Guidelines discuss cancers originating in the ovary, fallopian tube, or peritoneum, as these are all managed in a similar manner. Most of the recommendations are based on data from patients with the most common subtypes─high-grade serous and grade 2/3 endometrioid. The NCCN Guidelines also include recommendations specifically for patients with less common ovarian cancers, which in the guidelines include the following: carcinosarcoma, clear cell carcinoma, mucinous carcinoma, low-grade serous, grade 1 endometrioid, borderline epithelial, malignant sex cord-stromal, and malignant germ cell tumors. This manuscript focuses on certain aspects of primary treatment, including primary surgery, adjuvant therapy, and maintenance therapy options (including PARP inhibitors) after completion of first-line chemotherapy.
Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers
Tosun, Duygu , Aisen, Paul , Jack, Clifford R. , Jagust, William J. , Petersen, Ronald C. , Saykin, Andrew J. , Bollinger, James, Ovod, Vitaliy , Mawuenyega, Kwasi G., Bateman, Randall J. , Shaw, Leslie M. , Trojanowski, John Q. , Blennow, Kaj , Weiner, Michael W. , Tosun, Duygu , Jack, Clifford R , Jagust, William J , Zetterberg, Henrik , Saykin, Andrew J , Bateman, Randall J , Tosun, Duygu , Veitch, Dallas P. , Zetterberg, Henrik

Mayo Clinic

Brain Communications | February 3, 2021 | Volume: 3 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcab008 | PMID 33842885 Get It

Abstract In vivo gold standard for the ante-mortem assessment of brain β-amyloid pathology is currently β-amyloid positron emission tomography or cerebrospinal fluid measures of β-amyloid42 or the β-amyloid42/β-amyloid40 ratio. The widespread acceptance of a biomarker classification scheme for the Alzheimer’s disease continuum has ignited interest in more affordable and accessible approaches to detect Alzheimer’s disease β-amyloid pathology, a process that often slows down the recruitment into, and adds to the cost of, clinical trials. Recently, there has been considerable excitement concerning the value of blood biomarkers. Leveraging multidisciplinary data from cognitively unimpaired participants and participants with mild cognitive impairment recruited by the multisite biomarker study of Alzheimer’s Disease Neuroimaging Initiative, here we assessed to what extent plasma β-amyloid42/β-amyloid40, neurofilament light and phosphorylated-tau at threonine-181 biomarkers detect the presence of β-amyloid pathology, and to what extent the addition of clinical information such as demographic data, APOE genotype, cognitive assessments and MRI can assist plasma biomarkers in detecting β-amyloid-positivity. Our results confirm plasma β-amyloid42/β-amyloid40 as a robust biomarker of brain β-amyloid-positivity (area under curve, 0.80–0.87). Plasma phosphorylated-tau at threonine-181 detected β-amyloid-positivity only in the cognitively impaired with a moderate area under curve of 0.67, whereas plasma neurofilament light did not detect β-amyloid-positivity in either group of participants. Clinical information as well as MRI-score independently detected positron emission tomography β-amyloid-positivity in both cognitively unimpaired and impaired (area under curve, 0.69–0.81). Clinical information, particularly APOE ε4 status, enhanced the performance of plasma biomarkers in the detection of positron emission tomography β-amyloid-positivity by 0.06–0.14 units of area under curve for cognitively unimpaired, and by 0.21–0.25 units for cognitively impaired; and further enhancement of these models with an MRI-score of β-amyloid-positivity yielded an additional improvement of 0.04–0.11 units of area under curve for cognitively unimpaired and 0.05–0.09 units for cognitively impaired. Taken together, these multi-disciplinary results suggest that when combined with clinical information, plasma phosphorylated-tau at threonine-181 and neurofilament light biomarkers, and an MRI-score could effectively identify β-amyloid+ cognitively unimpaired and impaired (area under curve, 0.80–0.90). Yet, when the MRI-score is considered in combination with clinical information, plasma phosphorylated-tau at threonine-181 and plasma neurofilament light have minimal added value for detecting β-amyloid-positivity. Our systematic comparison of β-amyloid-positivity detection models identified effective combinations of demographics, APOE, global cognition, MRI and plasma biomarkers. Promising minimally invasive and low-cost predictors such as plasma biomarkers of β-amyloid42/β-amyloid40 may be improved by age and APOE genotype.
Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study
Sutton, Arnethea L. , Hurtado‐de‐Mendoza, Alejandra , He, Jun, Dahman, Bassam , Edmonds, Megan C. , Hackney, Mary Helen , Tadesse, Mahlet G. , Sutton, Arnethea L , Hackney, Mary Helen , Sheppard, Vanessa B.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 29, 2021 | Volume: 30 | Issue: 4 | Pages: 699-709

10.1158/1055-9965.epi-20-0604 | PMID 33514603 Get It

Abstract Background: Adjuvant endocrine therapy (AET) improves outcomes in women with hormone receptor–positive (HR+) breast cancer. Suboptimal AET adherence is common, but data are lacking about symptoms and adherence in racial/ethnic minorities. We evaluated adherence by race and the relationship between symptoms and adherence. Methods: The Women's Hormonal Initiation and Persistence study included women diagnosed with nonrecurrent HR+ breast cancer who initiated AET. AET adherence was captured using validated items. Data regarding patient (e.g., race), medication-related (e.g., symptoms), cancer care delivery (e.g., communication), and clinicopathologic factors (e.g., chemotherapy) were collected via surveys and medical charts. Multivariable logistic regression models were employed to calculate odds ratios and 95% confidence intervals (CIs) associated with adherence. Results: Of the 570 participants, 92% were privately insured and nearly one of three were Black. Thirty-six percent reported nonadherent behaviors. In multivariable analysis, women less likely to report adherent behaviors were Black (vs. White; OR, 0.43; 95% CI, 0.27–0.67; P < 0.001) and with greater symptom burden (OR, 0.98; 95% CI, 0.96–1.00; P < 0.05). Participants more likely to be adherent were overweight (vs. normal weight) (OR, 1.58; 95% CI, 1.04–2.43; P < 0.05), sat ≤ 6 hours a day (vs. ≥6 hours; OR, 1.83; 95% CI, 1.25–2.70; P < 0.01), and were taking aromatase inhibitors (vs. tamoxifen; OR, 1.91; 95% CI, 1.28–2.87; P < 0.01). Conclusions: Racial differences in AET adherence were observed. Longitudinal assessments of symptom burden are needed to better understand this dynamic process and factors that may explain differences in survivor subgroups. Impact: Future interventions should prioritize Black survivors and women with greater symptom burden.
Improving Access to Self-Expanding Metal Stents for Patients With Esophageal Cancer in Eastern Africa: A Stepwise Implementation Strategy
Mushi, Beatrice P. , Kaimila, Bongani , Mulima, Gift , Kelly, Paul , Akoko, Larry , Selekwa, Msiba , Ringo, Yona, Pritchett, Natalie , White, Russell E., Topazian, Mark , Fleischer, David E., Mwachiro, Michael , Buckle, Geoffrey Colin , Kayamba, Violet J. , Mmbaga, Elia John , Dawsey, Sanford M. , Loon, Katherine Van

Mayo Clinic

JCO Global Oncology | January 15, 2021 | Volume: No volume available | Issue: 7 | Pages: 118-126

10.1200/go.20.00318 | PMID 33449802 Get It

PURPOSE The eastern corridor of Africa is affected by a high burden of esophageal cancer (EC), with > 90% of patients presenting with advanced disease. Self-expanding metal stents (SEMS) have been previously reported as safe and effective for palliation of malignant dysphagia in resource-limited settings; however, access is limited throughout Eastern Africa. METHODS In response to demand for palliative interventions for patients with dysphagia because of EC, the African Esophageal Cancer Consortium (AfrECC) partnered with the Clinton Health Access Initiative to improve access to SEMS in Eastern Africa. We undertook a stepwise implementation approach to (1) identify barriers to SEMS access, (2) conduct a market analysis, (3) select an industry partner, (4) establish regulatory and procurement processes, (5) develop endoscopic training resources, (6) create a medical device registry, and (7) establish principles of accountability. RESULTS Following an evaluation of market demand and potential SEMS manufacturers, Boston Scientific Corporation announced its commitment to launch an access program to provide esophageal SEMS to patients in Tanzania, Kenya, Malawi, and Zambia at a subsidized price. Parallel regulatory and procurement processes were established in each participating country. Endoscopy training courses were designed and conducted, using the Training-of-Trainers model. A device registry was created to centralize data for quality control and to monitor channels of SEMS distribution. Principles of accountability were developed to guide the sustainability of this endeavor. CONCLUSION The AfrECC Stent Access Initiative is an example of a multisector partnership formed to provide an innovative solution to align regional needs with a supply chain for a high-priority medical device.
Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoproteinIgGassociated disorder: A comprehensive neuro‐ophthalmic review
Sharma, Jaya, Bhatti, M. Tariq , Danesh‐Meyer, Helen V.

Mayo Clinic

Clinical & Experimental Ophthalmology | January 15, 2021 | Volume: 49 | Issue: 2 | Pages: 186-202

10.1111/ceo.13863 | PMID 33426799 Get It

AbstractNeuromyelitis optica spectrum disorder (NMOSD) is an antibody‐mediated inflammatory disease of the central nervous system that involves the optic nerves, spinal cord, and often other specific brain regions such as area postrema of the medulla. NMOSD was formerly classified as a variant of multiple sclerosis (MS), given the similar symptomatology and relapsing course but is now considered to have distinct clinical, paraclinical, immunological and prognostic features. The discovery of aquaporin 4 (AQP4) immunoglobulin G (IgG) has improved the ability to diagnose NMOSD. AQP4‐IgG targets the astrocytic AQP4 water channel leading to complement activation and increased blood‐brain barrier permeability. Accurate and early diagnosis is crucial as timely treatment may result in mitigation of long‐term disability. Myelin oligodendrocyte glycoprotein (MOG)‐IgG associated disorder (MOGAD) is a distinct nosologic entity, which has been more recently described. Its clinical spectrum partly overlaps that of seronegative NMOSD and MS. Although it is considered to have fewer relapses and better prognosis than NMOSD, the clinical course and outcome of MOGAD has not been fully characterized.
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Daly, Mary B., Dickson, Patricia , Elkhanany, Ahmed , Friedman, Susan , Hutton, Mollie L., CGC, Khan, Seema, Klein, Catherine, Kohlmann, Wendy , CGC, Kurian, Allison W. , Laronga, Christine , Mak, Julie , LCGC, Menendez, Carolyn S. , Merajver, Sofía D. , Norquist, Barbara S., Offit, Kenneth , Pederson, Holly J. , Reiser, Gwen , CGC, Senter-Jamieson, Leigha, CGC, Shannon, Kristen M. , Shatsky, Rebecca , Visvanathan, Kala , Weitzel, Jeffrey N. , Wick, Myra , Wisinski, Kari B. , Yurgelun, Matthew B. , Darlow, Susan, Dwyer, Mary A., Norquist, Barbara M. , Weitzel, Jeffrey N , Visvanathan, Kala , Kurian, Allison W , Norquist, Barbara , Elkhanany, Ahmed , Shatsky, Rebecca , Pal, Tuya , Berry, Michael P., Buys, Saundra S. , Domchek, Susan M. , Goggins, Michael , CGC, Karlan, Beth Y. , CGC, Litton, Jennifer K. , LCGC, CGC, CGC

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 6, 2021 | Volume: 19 | Issue: 1 | Pages: 77-102

10.6004/jnccn.2021.0001 | PMID 33406487 Get It

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and recommended approaches to genetic testing/counseling and management strategies in individuals with these pathogenic or likely pathogenic variants. This manuscript focuses on cancer risk and risk management for BRCA-related breast/ovarian cancer syndrome and Li-Fraumeni syndrome. Carriers of a BRCA1/2 pathogenic or likely pathogenic variant have an excessive risk for both breast and ovarian cancer that warrants consideration of more intensive screening and preventive strategies. There is also evidence that risks of prostate cancer and pancreatic cancer are elevated in these carriers. Li-Fraumeni syndrome is a highly penetrant cancer syndrome associated with a high lifetime risk for cancer, including soft tissue sarcomas, osteosarcomas, premenopausal breast cancer, colon cancer, gastric cancer, adrenocortical carcinoma, and brain tumors.
Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents
Wolf, Joshua , Abzug, Mark J., Wattier, Rachel L , Sue, Paul K. , Vora, Surabhi B , Zachariah, Philip , Waghmare, Alpana , Olivero, Rosemary , Downes, Kevin J. , James, Scott H. , Pinninti, Swetha , Yarbrough, April , Aldrich, Margaret, MacBrayne, Christine E. , Soma, Vijaya L, Grapentine, Steven P, Oliveira, Carlos R. , Hayes, Molly , Kimberlin, David W. , Jones, Sarah Bruyn, Bio, Laura , Morton, Ted , Hankins, Jane S. , Marón, Gabriela , Timberlake, Kathryn , Orscheln, Rachel C. , Schwenk, Hayden T. , Goldman, David L., Groves, Helen , Rajapakse, Nipunie , Lamb, Gabriella S , Tribble, Alison C. , Lloyd, Elizabeth C , Hersh, Adam L. , Thorell, Emily A., Ratner, Adam J. , Nakamura, Mari , Waghmare, Alpana , Downes, Kevin J , Rajapakse, Nipunie S, Ratner, Adam J , Hankins, Jane S , Schwenk, Hayden T , Wolf, Joshua , Oliveira, Carlos R , Dulek, Daniel E. , Jones, Sarah B, Young, Jennifer L, Huskins, W. Charles , Chiotos, Kathleen

Mayo Clinic

Journal of the Pediatric Infectious Diseases Society | December 26, 2020 | Volume: 10 | Issue: 5 | Pages: 629-634

10.1093/jpids/piaa175 | PMID 33388760 Get It

Abstract Background In November 2020, the US Food and Drug Administration (FDA) provided Emergency Use Authorizations (EUA) for 2 novel virus-neutralizing monoclonal antibody therapies, bamlanivimab and REGN-COV2 (casirivimab plus imdevimab), for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adolescents and adults in specified high-risk groups. This has challenged clinicians to determine the best approach to use of these products. Methods A panel of experts in pediatric infectious diseases, pediatric infectious diseases pharmacy, pediatric intensive care medicine, and pediatric hematology from 29 geographically diverse North American institutions was convened. Through a series of teleconferences and web-based surveys, a guidance statement was developed and refined based on review of the best available evidence and expert opinion. Results The course of COVID-19 in children and adolescents is typically mild and there is no high-quality evidence supporting any high-risk groups. There is no evidence for safety and efficacy of monoclonal antibody therapy for treatment of COVID-19 in children or adolescents, limited evidence of modest benefit in adults, and evidence for potential harm associated with infusion reactions or anaphylaxis. Conclusions Based on evidence available as of December 20, 2020, the panel suggests against routine administration of monoclonal antibody therapy (bamlanivimab, or casirivimab and imdevimab), for treatment of COVID-19 in children or adolescents, including those designated by the FDA as at high risk of progression to hospitalization or severe disease. Clinicians and health systems choosing to use these agents on an individualized basis should consider risk factors supported by pediatric-specific evidence and ensure the implementation of a system for safe and timely administration that does not exacerbate existing healthcare disparities.
Author response: TFEB/Mitf links impaired nuclear import to autophagolysosomal dysfunction in C9-ALS
Cunningham, Kathleen M. , Maulding, Kirstin , Ruan, Kai , Grima, Jonathan C., Sung, Hyun , Zuo, Zhongyuan , Song, Helen, Gao, Junli , Dubey, Sandeep Kumar , Şentürk, Mümine , Rothstein, Jeffrey D. , Zhang, Ke , Bellen, Hugo J. , Lloyd, Thomas E

Mayo Clinic

No container title available | December 23, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.59419.sa2 Get It